The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor
Abstract
Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal proliferation of transformed myofibroblasts, with a prominent inflammatory cell component, that can mimic other spindle cell processes such as nodular fasciitis, desmoid tumor, and gastrointestinal stromal tumor. Genetic analyses have recently demonstrated rearrangements of anaplastic lymphoma kinase (ALK), located at 2p23, in a subset of IMTs. Molecular characterizations have identified ALK fusions involving tropomyosin‐3 and ‐4 (TPM‐3 and ‐4), the clathrin heavy chain (CLTC), and the cysteinyl‐tRNA synthetase (CARS) genes as fusion partners. Here we describe two IMTs with a novel ALK fusion that involves the Ran‐binding protein 2 (RANBP2) gene at 2q13, which normally encodes a large (358‐kDa) nucleopore protein localized at the cytoplasmic side of the nuclear pore complex. The N‐terminal 867 residues of RANBP2 are fused to the cytoplasmic segment of ALK in the 1,430–amino acid RANBP2‐ALK chimeric protein. Myofibroblasts that express RANBP2‐ALK exhibit nuclear membrane‐associated ALK staining that is unique compared to the subcellular localization observed with other ALK fusions in IMT, presumably attributable to heteroassociation of the fusion with normal RANBP2 at the nuclear pore. These findings expand the spectrum of ALK abnormalities observed in IMT and further confirm the clonal, neoplastic nature of these lesions. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
Self-citationMahajan, R., Delphin, C., Guan, T., Gerace, L., & Melchior, F. (1997) · Cell · doi:10.1016/s0092-8674(00)81862-0 · Cited by 1,256
The Nucleoporin RanBP2 Has SUMO1 E3 Ligase Activity
Pichler, A., Gast, A., Seeler, J. S., Dejean, A., & Melchior, F. (2002) · Cell · doi:10.1016/s0092-8674(01)00633-x · Cited by 816
Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.
Griffin, C. A., Hawkins, A. L., Dvorak, C. C., Henkle, C., Ellingham, T. J., & Perlman, E. J. (1999) · PubMed · Cited by 571
A giant nucleopore protein that binds Ran/TC4
Yokoyama, N., Hayashi, N., Seki, T., Panté, N., Ohba, T., Nishii, K., Kuma, K., Hayashida, T., Miyata, T., Aebi, U., et al. (1995) · Nature · doi:10.1038/376184a0 · Cited by 498
Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey.
Coffin, C. M., Humphrey, P. A., & Dehner, L. P. (1998) · PubMed · Cited by 431
Fusion of the ALK Gene to the Clathrin Heavy Chain Gene, CLTC, in Inflammatory Myofibroblastic Tumor
Bridge, J. A., Kanamori, M., Ma, Z., Pickering, D., Hill, D. A., Lydiatt, W., Lui, M. Y., Colleoni, G. W. B., Antonescu, C. R., Ladanyi, M., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61711-7 · Cited by 359
Self-citationVetter, I. R., Nowak, C., Nishimoto, T., Kuhlmann, J., & Wittinghofer, A. (1999) · Nature · doi:10.1038/17969 · Cited by 313
Cools, J., Włodarska, I., Somers, R., et al. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10033 · Cited by 292
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Coffin, C. M., Hornick, J. L., & Fletcher, C. D. M. (2007) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213393.57322.c7 · Cited by 1,006
The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2291 · Cited by 882
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Butrynski, J. E., D'Adamo, D. R., Hornick, J. L., Dal Cin, P., Antonescu, C. R., Jhanwar, S. C., Ladanyi, M., Capelletti, M., Rodig, S. J., Ramaiya, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007056 · Cited by 870
Inflammatory myofibroblastic tumours: where are we now?
Gleason, B. C., & Hornick, J. L. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.049387 · Cited by 757
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Hallberg, B., & Palmer, R. H. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3580 · Cited by 645
Targeting ALK: Precision Medicine Takes on Drug Resistance
Lin, J. J., Riely, G. J., & Shaw, A. T. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1123 · Cited by 522
Anaplastic lymphoma kinase: signalling in development and disease
Palmer, R. H., Vernersson, E., Grabbe, C., & Hallberg, B. (2009) · Biochemical Journal · doi:10.1042/bj20090387 · Cited by 423
Mariño-Enríquez, A., Wang, W.-L., Roy, A., Lopez-Terrada, D., Lazar, A. J. F., Fletcher, C. D. M., Coffin, C. M., & Hornick, J. L. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318200cfd5 · Cited by 389
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 303
Nuclear Receptor Coregulators and Human Disease
Lonard, D. M., Lanz, R. B., & O’Malley, B. W. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0012 · Cited by 302
Gascoyne, R. D. (2003) · Blood · doi:10.1182/blood-2003-03-0786 · Cited by 297
Togashi, Y., Soda, M., Sakata, S., Sugawara, E., Hatano, S., Asaka, R., Nakajima, T., Mano, H., & Takeuchi, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031323 · Cited by 267
Treating ALK-positive lung cancer—early successes and future challenges
Camidge, D. R., & Doebele, R. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.43 · Cited by 236
Metadata
- Authors
- Ma, Z., Hill, D. A., Collins, M. H., Morris, S. W., Sumegi, J., Zhou, M., Zuppan, C., & Bridge, J. A.
- Venue
- Genes, Chromosomes and Cancer
- Publisher
- Wiley
- Published
- 2003-03-11
- Volume
- 37
- Issue
- 1
- Pages
- 98-105
- ISSN
- 1045-2257 (ISSN-L)
- 1098-2264
- OpenAlex
- W2141638508
- Cited by
- 280
- References
- 19
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.